http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
-
FDA approves NOVN's Leqvio for first-line cholesterol treatment
-
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
-
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
-
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
-
Novartis receives third FDA approval for oral Fabhalta
-
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
-
Novartis named corporate pharmaceutical partner of the NFL
-
Novartis named first-ever corporate pharmaceutical partner of the National Football League
-
Early detection is a game changer: Novartis makes bold play to prioritize breast health and inspire a new wave of breast cancer screenings
-
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
-
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
-
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
-
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
-
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
-
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
-
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
-
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
-
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
-
New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies
-
FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies
-
MorphoSys AG (MOR) to be Acquired by Novartis for EUR 2.7B Equity Value
-
Novartis (NVS) Expands Production of Pluvicto
-
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
-
Novartis (NVS) Presents new 48-week Results from Phase III APPLY-PNH Study
-
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
-
Novartis announced FDA approval for Fabhalta
-
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
-
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
-
Novartis (NVS) Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune Oral Solution, 100 mg/mL due to Crystallization
-
Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
-
FDA approves Novartis (NVS) Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases
-
FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases
-
Novartis (NVS) Issues Voluntary Nationwide Recall of One Lot of Sandimmune Oral Solution, 100 mg/mL due to Crystallization
-
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
-
Earnings wave, Novartis guidance, ARK's Twitter stake - what's moving markets
-
Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers
-
Novartis (NVS) announces FDA approves expanded indication for Leqvio
-
US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
-
Novartis premieres powerful new docuseries at Tribeca Festival to shine a light on debilitating skin disease
-
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
-
Novartis's (NVS) Kisqali Cut Risk Of Tumors Returning By 25%
-
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
-
Ligand Reports First Quarter 2023 Financial Results
-
Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
-
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
-
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
-
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
-
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
-
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
